Should I Buy MMSI? MMSI 2026 Analysis

Should You Buy Merit Medical Systems Inc (MMSI) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

82.500

1 Day change

3.60%

52 Week Range

110.670

Analysis Updated At

2026/02/05

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now for an impatient entry: the trend setup is still bearish (SMA_200 > SMA_20 > SMA_5) and there are no Intellectia buy signals today.
Upside exists vs. Street price targets ($93–$108) with the stock at ~$80.78, but near-term technicals and muted options activity suggest no strong immediate momentum.
Best stance today: HOLD (wait for a clearer upside break above ~$82.84 resistance or a stronger signal/volume confirmation).

Technical Analysis

Trend/structure: Bearish alignment (SMA_200 > SMA_20 > SMA_5) signals the broader trend is still down/weak.
Momentum: MACD histogram -0.14 (below zero) but negatively contracting, implying downside momentum is easing, not reversing yet.
RSI(6) ~44.1: neutral-to-slightly weak; not oversold, so no strong mean-reversion buy signal.
Key levels: Pivot ~81.24 (price 80.78 is just below), Support S1 ~79.63 then S2 ~78.64; Resistance R1 ~82.84 then R2 ~83.83.
Pattern-based odds: Similar-pattern model implies mild short-term upside (next day/week) but negative bias over the next month (-2.06%), aligning with a “not-yet” trend picture.

Options Data

Neutral

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Positioning: Open interest put/call ~0.98 is essentially neutral (no strong bullish or bearish crowding).
Activity: Reported options volume is 0 today; sentiment read-through from volume is effectively unavailable/low-conviction.
Volatility: 30D IV ~31.43 vs historical vol ~35.27; IV percentile ~42.63 (mid-range). No clear “priced-in” big move signal from options.
Takeaway: Options market is not currently signaling a high-conviction bullish entry.

Technical Summary

Sell

Buy

Positive Catalysts

- Analyst stance is broadly constructive (Buy/Outperform/Overweight), with raised targets in mid-Dec 2025 pointing to improving 2026 outlook for Med-Tech.
- Core business momentum remains a recurring positive in analyst commentary, even amid Wrapsody reimbursement timing issues.
- Upcoming earnings: QDEC 2025 earnings on 2026-02-24 (After Hours) could be a catalyst if results/guide beat expectations.

Neutral/Negative Catalysts

- Technical trend remains bearish (moving averages stacked against the stock), reducing odds of a strong immediate breakout without confirmation.
- Wrapsody reimbursement/TPT delay into 2027 previously hurt upside narrative and management credibility (per analyst notes), which can cap multiple expansion.
- No recent news flow and negligible options volume today = fewer immediate sentiment-driven catalysts.
- Congress trading: No recent congress trading data available (no supportive “influential buyer” signal).

Financial Performance

Latest reported quarter: 2025/Q3.
Revenue: $384.16M, +13.04% YoY (strong top-line growth).
Profitability: Net income $27.76M, -2.42% YoY; EPS $0.46, -4.17% YoY (growth is not fully translating to bottom line yet).
Margins: Gross margin 48.52%, +4.68% YoY (a clear operational positive).
Read-through: Healthy demand and improving gross margin, but earnings growth is currently lagging revenue growth.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent rating/target trend: Net positive.
- 2025-12-16: Baird raised PT to $108 (Outperform).
- 2025-12-17: Canaccord raised PT to $99 (Buy).
- 2025-11-14: Canaccord cut PT to $93 (Buy) on CMS/Wrapsody timing uncertainty.
- 2025-11-14: Wells Fargo cut PT to $95 (Overweight) citing TPT delay to 2027 but emphasized strong core momentum.
Wall Street pros: Strong core business momentum, supportive Med-Tech demand backdrop, meaningful upside to PTs from current price.
Wall Street cons: Wrapsody reimbursement/timing and execution credibility overhang; recent operational narrative risk can delay re-rating.
Flows/behavior: Hedge funds neutral (no significant trend last quarter); insiders neutral (no significant trend last month).

8 Analyst Rating

Wall Street analysts forecast MMSI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MMSI is 104.63 USD with a low forecast of 90 USD and a high forecast of 122 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

7 Buy

1 Hold

0 Sell

Strong Buy

Current: 79.630

Low

Averages

104.63

High

122

Current: 79.630

Low

Averages

104.63

High

122

BTIG

initiated

$107

AI Analysis

2026-02-06

New

Reason

BTIG

Price Target

$107

AI Analysis

2026-02-06

New

initiated

Reason

BTIG initiated coverage of Merit Medical with a Buy rating and $107 price target. Merit is a global medical device company with a "comprehensive" portfolio of products that are used across a broad range of interventional procedures, the analyst tells investors in a research note. The firm sees the company's end markets remaining "healthy" given rising cardiovascular disease prevalence and Merit 's stable competitive position. With forward expectations achievable and the stock trading at one standard deviation below its historical average, current levels offer an attractive entry point, contends BTIG.

Canaccord

Buy

maintain

$93 -> $99

2025-12-17

Reason

Canaccord

Price Target

$93 -> $99

2025-12-17

maintain

Buy

Reason

Canaccord raised the firm's price target on Merit Medical to $99 from $93 and keeps a Buy rating on the shares. The firm said they continue to be bullish on the Med-Tech sector heading into 2026. They point to strong underlying demand from an aging population, a focus on acute healthcare needs, the healthy pace of M&A, and a market that is receptive to IPOs as the foundation for our belief in our positive outlook in the upcoming year.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for MMSI

Unlock Now

MMSI Should I Buy

MMSI Should I Buy

Should You Buy Merit Medical Systems Inc (MMSI) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch